Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nuzefatide pevedotin + nivolumab
- Development stage
- Phase 2
- Lead developer
- Bicycle Therapeutics
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Nuzefatide pevedotin + nivolumab** is an investigational combination therapy consisting of nuzefatide pevedotin (formerly BT5528), an EphA2-targeting Bicycle Drug Conjugate (BDC), and nivolumab, a programmed death-1 (PD-1) blocking monoclonal antibody. Nuzefatide pevedotin comprises a bicyclic peptide targeting erythropoietin-producing hepatocellular receptor A2 (EphA2) conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a cleavable linker. Nivolumab is an IgG4 monoclonal antibody that binds to PD-1, preventing its interaction with PD-L1 and PD-L2 to restore T-cell mediated anti-tumor immune responses. This combination is being evaluated in Phase 1/2 clinical trials for the treatment of advanced solid tumors, including metastatic urothelial carcinoma (mUC), ovarian cancer, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), and gastric/upper gastrointestinal cancer.
- Other names
- BT5528 + nivolumabBT5528 + Opdivonuzefatide pevedotin + Opdivo
02
Targets
EPHA2 (Ephrin type-A receptor 2)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nuzefatide pevedotin + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nuzefatide pevedotin + nivolumab.